Difficult-to-make medicines - making a difference in generics

At Sandoz, we make far more than just traditional off-patent products. We stand out from the crowd thanks to our ability, honed through decades of experience, to add value for patients by producing new and “difficult-to-make” generic medicines.

Our broad portfolio of difficult-to-make generics ranges from advanced application forms such as oral solids, through progressively more complex technologies such as inhalers or injectables to transdermal patches and implants. At the top of the technological pyramid is our pioneering position in the rapidly emerging market for biosimilars (authorized versions of existing biopharmaceuticals).

The graphic below gives an idea of the scope of our difficult-to-make portfolio. The Sandoz centers of excellence are currently working on 900 further development projects, including many in the field of biotechnology.

Difficult-to-make - how we make a difference